In the CD14+ fraction, few non-CD14+ cells were present (see Materials and Methods), and in the CD19+ fraction of CLL patients, no difference in killing in the presence or absence of KAND567 was noted, substantiating that the killing effect of KAND567 was mediated through CD14+ cells. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.